Guangzhou LBP Medicine Science & Technology Co Ltd
688393
Company Profile
Business description
Guangzhou LBP Medicine Science & Technology Co Ltd is engaged in production and sales of in vitro diagnostic reagents and instruments. The company's products include Fluorescence in situ hybridization (FISH) series; Immunohistochemistry (IHC) series; Liquid - based cytology (LBP) series; PCR series; and medical laboratory.
Contact
Building 7, No. 11, Nanxiang 3rd Road
Guangzhou High-tech Industrial Development Zone
Guangdong Province
Guangzhou510663
CHNT: +86 2032299997
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
768
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,218.24 | 26.05 | -0.32% |
| DAX 40 | 24,759.05 | 185.90 | -0.75% |
| Dow JONES (US) | 51,134.69 | 427.24 | -0.83% |
| FTSE 100 | 10,368.05 | 7.73 | 0.07% |
| HKSE | 24,961.95 | 291.45 | -1.15% |
| NASDAQ | 26,037.61 | 793.35 | -2.96% |
| Nikkei 225 | 66,588.12 | 882.57 | -1.31% |
| NZX 50 Index | 13,161.97 | 60.36 | 0.46% |
| S&P 500 | 7,450.81 | 133.50 | -1.76% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 4,027.74 | 30.04 | -0.74% |